Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Axel Schambach is active.

Publication


Featured researches published by Axel Schambach.


Science Translational Medicine | 2014

Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity

Christian Jörg Braun; Kaan Boztug; Anna Paruzynski; Maximilian Witzel; Adrian Schwarzer; Michael Rothe; Ute Modlich; Rita Beier; Gudrun Göhring; Doris Steinemann; Raffaele Fronza; Claudia R. Ball; Reinhard Haemmerle; Sonja Naundorf; Klaus Kühlcke; Martina Rose; Chris Fraser; Liesl Mathias; Rudolf Ferrari; Miguel R. Abboud; Waleed Al-Herz; Irina Kondratenko; László Maródi; Hanno Glimm; Brigitte Schlegelberger; Axel Schambach; Michael H. Albert; Manfred Schmidt; Christof von Kalle; Christoph Klein

Wiskott-Aldrich syndrome gene therapy is feasible, but γ-retroviral vectors contribute a substantial risk of leukemogenesis. Taking the Sting Out of Gene Therapy Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disorder characterized by low platelet count, immune deficiency, autoimmunity, and high risk of cancer. WAS is primarily a disorder of blood cells, and hematopoietic stem cell transplantation (HSCT) has been the only hope of cure. However, HSCT is restricted to patients who can find matching donors. One way to overcome this limitation is through gene therapy that restores the function of the mutated protein in HSCs from the patient. Now, Braun et al. report correction of WAS protein (WASP) in 9 of 10 patients that underwent HSC gene therapy. The authors used a γ-retroviral vector to correct WASP expression in autologous HSCs. After transfer to patients, these cells engrafted and WASP was expressed in lymphoid and myeloid cells and platelets in 9 of 10 patients. What’s more, this therapy caused either partial or complete resolution of symptoms. However, seven patients developed acute leukemia, and further analysis revealed genetic alterations such as chromosomal translocations. These studies suggest that with improved vector design, gene therapy may be feasible and effective for patient with WAS. Wiskott-Aldrich syndrome (WAS) is characterized by microthrombocytopenia, immunodeficiency, autoimmunity, and susceptibility to malignancies. In our hematopoietic stem cell gene therapy (GT) trial using a γ-retroviral vector, 9 of 10 patients showed sustained engraftment and correction of WAS protein (WASP) expression in lymphoid and myeloid cells and platelets. GT resulted in partial or complete resolution of immunodeficiency, autoimmunity, and bleeding diathesis. Analysis of retroviral insertion sites revealed >140,000 unambiguous integration sites and a polyclonal pattern of hematopoiesis in all patients early after GT. Seven patients developed acute leukemia [one acute myeloid leukemia (AML), four T cell acute lymphoblastic leukemia (T-ALL), and two primary T-ALL with secondary AML associated with a dominant clone with vector integration at the LMO2 (six T-ALL), MDS1 (two AML), or MN1 (one AML) locus]. Cytogenetic analysis revealed additional genetic alterations such as chromosomal translocations. This study shows that hematopoietic stem cell GT for WAS is feasible and effective, but the use of γ-retroviral vectors is associated with a substantial risk of leukemogenesis.


Molecular Therapy | 2008

Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors

Daniela Zychlinski; Axel Schambach; Ute Modlich; Tobias Maetzig; Johann Meyer; Elke Grassman; Anjali Mishra; Christopher Baum

The possible activation of cellular proto-oncogenes as a result of clonal transformation is a potential limitation in a therapeutic approach involving random integration of gene vectors. Given that enhancer promiscuity represents an important mechanism of insertional transformation, we assessed the enhancer activities of various cellular and retroviral promoters in transient transfection assays, and also in a novel experimental system designed to measure the activation of a minigene cassette contained in stably integrating retroviral vectors. Retroviral enhancer-promoters showed a significantly greater potential to activate neighboring promoters than did cellular promoters derived from human genes, elongation factor-1alpha (EF1alpha) and phosphoglycerate kinase (PGK). Self-inactivating (SIN) vector design reduced but did not abolish enhancer interactions. Using a recently established cell culture assay that detects insertional transformation by serial replating of primary hematopoietic cells, we found that SIN vectors containing the EF1alpha promoter greatly decrease the risk of insertional transformation. Despite integration of multiple copies per cell, activation of the crucial proto-oncogene Evi1 was not detectable when using SIN-EF1alpha vectors. On the basis of several quantitative indicators, the decrease in transforming activity was highly significant (more than tenfold, P < 0.01) when compared with similarly designed vectors containing a retroviral enhancer-promoter with or without a well-characterized genetic insulator core element. In this manner, the insertional biosafety of therapeutic gene vectors can be greatly enhanced and proactively evaluated in sensitive cell-based assays.


Cell | 2012

A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage

Jianwei Wang; Qian Sun; Yohei Morita; Hong Jiang; Alexander Groß; André Lechel; Kai Hildner; Luis Miguel Guachalla; Anne Gompf; Daniel Hartmann; Axel Schambach; Torsten Wuestefeld; Daniel Dauch; Hubert Schrezenmeier; Wolf-Karsten Hofmann; Hiromitsu Nakauchi; Zhenyu Ju; Hans A. Kestler; Lars Zender; K. Lenhard Rudolph

Checkpoints that limit stem cell self-renewal in response to DNA damage can contribute to cancer protection but may also promote tissue aging. Molecular components that control stem cell responses to DNA damage remain to be delineated. Using in vivo RNAi screens, we identified basic leucine zipper transcription factor, ATF-like (BATF) as a major component limiting self-renewal of hematopoietic stem cells (HSCs) in response to telomere dysfunction and γ-irradiation. DNA damage induces BATF in a G-CSF/STAT3-dependent manner resulting in lymphoid differentiation of HSCs. BATF deletion improves HSC self-renewal and function in response to γ-irradiation or telomere shortening but results in accumulation of DNA damage in HSCs. Analysis of bone marrow from patients with myelodysplastic syndrome supports the conclusion that DNA damage-dependent induction of BATF is conserved in human HSCs. Together, these results provide experimental evidence that a BATF-dependent differentiation checkpoint limits self-renewal of HSCs in response to DNA damage.


Biotechnology and Bioengineering | 2012

Skin tissue generation by laser cell printing

Lothar Koch; Andrea Deiwick; Sabrina Schlie; Stefanie Michael; Martin Gruene; Vincent Coger; Daniela Zychlinski; Axel Schambach; Kerstin Reimers; Peter M. Vogt; Boris N. Chichkov

For the aim of ex vivo engineering of functional tissue substitutes, Laser‐assisted BioPrinting (LaBP) is under investigation for the arrangement of living cells in predefined patterns. So far three‐dimensional (3D) arrangements of single or two‐dimensional (2D) patterning of different cell types have been presented. It has been shown that cells are not harmed by the printing procedure. We now demonstrate for the first time the 3D arrangement of vital cells by LaBP as multicellular grafts analogous to native archetype and the formation of tissue by these cells. For this purpose, fibroblasts and keratinocytes embedded in collagen were printed in 3D as a simple example for skin tissue. To study cell functions and tissue formation process in 3D, different characteristics, such as cell localisation and proliferation were investigated. We further analysed the formation of adhering and gap junctions, which are fundamental for tissue morphogenesis and cohesion. In this study, it was demonstrated that LaBP is an outstanding tool for the generation of multicellular 3D constructs mimicking tissue functions. These findings are promising for the realisation of 3D in vitro models and tissue substitutes for many applications in tissue engineering. Biotechnol. Bioeng. 2012; 109:1855–1863.


The New England Journal of Medicine | 2014

A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency

Salima Hacein-Bey-Abina; Sung-Yun Pai; H. Bobby Gaspar; Myriam Armant; Charles C. Berry; Stéphane Blanche; Jack Bleesing; Johanna Blondeau; Helen de Boer; Karen Buckland; Laure Caccavelli; Guilhem Cros; Satir De Oliveira; Karen S. Fernández; Dongjing Guo; Chad E. Harris; Gregory Hopkins; Leslie Lehmann; Annick Lim; Wendy B. London; Johannes C.M. van der Loo; Nirav Malani; Frances Male; Punam Malik; M. Angélica Marinovic; Anne Marie McNicol; Despina Moshous; Bénédicte Neven; Matías Oleastro; Capucine Picard

BACKGROUND In previous clinical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine leukemia virus-based γ-retrovirus vector expressing interleukin-2 receptor γ-chain (γc) complementary DNA successfully restored immunity in most patients but resulted in vector-induced leukemia through enhancer-mediated mutagenesis in 25% of patients. We assessed the efficacy and safety of a self-inactivating retrovirus for the treatment of SCID-X1. METHODS We enrolled nine boys with SCID-X1 in parallel trials in Europe and the United States to evaluate treatment with a self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc). RESULTS All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning. After 12.1 to 38.7 months of follow-up, eight of the nine children were still alive. One patient died from an overwhelming adenoviral infection before reconstitution with genetically modified T cells. Of the remaining eight patients, seven had recovery of peripheral-blood T cells that were functional and led to resolution of infections. The patients remained healthy thereafter. The kinetics of CD3+ T-cell recovery was not significantly different from that observed in previous trials. Assessment of insertion sites in peripheral blood from patients in the current trial as compared with those in previous trials revealed significantly less clustering of insertion sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients. CONCLUSIONS This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1. The long-term effect of this therapy on leukemogenesis remains unknown. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01410019, NCT01175239, and NCT01129544.).


Blood | 2012

The phenotype of human STK4 deficiency.

Hengameh Abdollahpour; Giridharan Appaswamy; Daniel Kotlarz; Diestelhorst J; Rita Beier; Alejandro A. Schäffer; Gertz Em; Axel Schambach; Hans-Heinrich Kreipe; Dietmar Pfeifer; Karin R. Engelhardt; Nima Rezaei; Bodo Grimbacher; Lohrmann S; Roya Sherkat; Christoph Klein

We describe a novel clinical phenotype associating T- and B-cell lymphopenia, intermittent neutropenia, and atrial septal defects in 3 members of a consanguineous kindred. Their clinical histories included recurrent bacterial infections, viral infections, mucocutaneous candidiasis, cutaneous warts, and skin abscesses. Homozygosity mapping and candidate gene sequencing revealed a homozygous premature termination mutation in the gene STK4 (serine threonine kinase 4, formerly having the symbol MST1). STK4 is the human ortholog of Drosophila Hippo, the central constituent of a highly conserved pathway controlling cell growth and apoptosis. STK4-deficient lymphocytes and neutrophils exhibit enhanced loss of mitochondrial membrane potential and increased susceptibility to apoptosis. STK4 deficiency is a novel human primary immunodeficiency syndrome.


Molecular Therapy | 2011

Lentiviral Vector Design and Imaging Approaches to Visualize the Early Stages of Cellular Reprogramming

Eva Warlich; Johannes Kuehle; Tobias Cantz; Martijn H. Brugman; Tobias Maetzig; Melanie Galla; Adam Filipczyk; Stephan Halle; Hannes Klump; Hans R. Schöler; Christopher Baum; Timm Schroeder; Axel Schambach

Induced pluripotent stem cells (iPSCs) can be derived from somatic cells by gene transfer of reprogramming transcription factors. Expression levels of these factors strongly influence the overall efficacy to form iPSC colonies, but additional contribution of stochastic cell-intrinsic factors has been proposed. Here, we present engineered color-coded lentiviral vectors in which codon-optimized reprogramming factors are co-expressed by a strong retroviral promoter that is rapidly silenced in iPSC, and imaged the conversion of fibroblasts to iPSC. We combined fluorescence microscopy with long-term single cell tracking, and used live-cell imaging to analyze the emergence and composition of early iPSC clusters. Applying our engineered lentiviral vectors, we demonstrate that vector silencing typically occurs prior to or simultaneously with the induction of an Oct4-EGFP pluripotency marker. Around 7 days post-transduction (pt), a subfraction of cells in clonal colonies expressed Oct4-EGFP and rapidly expanded. Cell tracking of single cell-derived iPSC colonies supported the concept that stochastic epigenetic changes are necessary for reprogramming. We also found that iPSC colonies may emerge as a genetic mosaic originating from different clusters. Improved vector design with continuous cell tracking thus creates a powerful system to explore the subtle dynamics of biological processes such as early reprogramming events.


Nature Medicine | 2009

NAMPT is essential for the G-CSF–induced myeloid differentiation via a NAD+–sirtuin-1–dependent pathway

Julia Skokowa; Dan Lan; Basant Kumar Thakur; Fei Wang; Kshama Gupta; Gunnar Cario; Annette Müller Brechlin; Axel Schambach; Lars Hinrichsen; Gustav Meyer; Matthias Gaestel; Martin Stanulla; Qiang Tong; Karl Welte

We identified nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B cell colony enhancing factor (PBEF), as an essential enzyme mediating granulocyte colony-stimulating factor (G-CSF)-triggered granulopoiesis in healthy individuals and in individuals with severe congenital neutropenia. Intracellular NAMPT and NAD+ amounts in myeloid cells, as well as plasma NAMPT and NAD+ levels, were increased by G-CSF treatment of both healthy volunteers and individuals with congenital neutropenia. NAMPT administered both extracellularly and intracellularly induced granulocytic differentiation of CD34+ hematopoietic progenitor cells and of the promyelocytic leukemia cell line HL-60. Treatment of healthy individuals with high doses of vitamin B3 (nicotinamide), a substrate of NAMPT, induced neutrophilic granulocyte differentiation. The molecular events triggered by NAMPT include NAD+-dependent sirtuin-1 activation, subsequent induction of CCAAT/enhancer binding protein-α and CCAAT/enhancer binding protein-β, and, ultimately, upregulation of G-CSF synthesis and G-CSF receptor expression. G-CSF, in turn, further increases NAMPT levels. These results reveal a decisive role of the NAD+ metabolic pathway in G-CSF-triggered myelopoiesis.


Nature | 2006

Gene therapy - X-SCID transgene leukaemogenicity

Adrian J. Thrasher; H. B. Gaspar; Christopher Baum; Ute Modlich; Axel Schambach; Fabio Candotti; Makoto Otsu; B. Sorrentino; Linda Scobie; Ewan R. Cameron; Karen Blyth; James C. Neil; S.H.-B. Abina; Marina Cavazzana-Calvo; Alain Fischer

Arising from: Woods, N.-B., Bottero, V., Schmidt, M., von Kalle, C. & Verma, I. M. 440, 1123 (2006); see also communication from Pike-Overzet et al.; Woods et al. replyGene therapy has been remarkably effective for the immunological reconstitution of patients with severe combined immune deficiency, but the occurrence of leukaemia in a few patients has stimulated debate about the safety of the procedure and the mechanisms of leukaemogenesis. Woods et al. forced high expression of the corrective therapeutic gene IL2RG, which encodes the γ-chain of the interleukin-2 receptor, in a mouse model of the disease and found that tumours appeared in a proportion of cases. Here we show that transgenic IL2RG does not necessarily have potent intrinsic oncogenic properties, and argue that the interpretation of this observation with respect to human trials is overstated.


Journal of Experimental Medicine | 2013

Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome

Daniel Kotlarz; Natalia Ziętara; Gulbu Uzel; Thomas Weidemann; Christian Braun; Jana Diestelhorst; Peter Krawitz; Peter N. Robinson; Jochen Hecht; Jacek Puchałka; E. Michael Gertz; Alejandro A. Schäffer; Monica G. Lawrence; Lela Kardava; Dietmar Pfeifer; Ulrich Baumann; Eva-Doreen Pfister; Eric P. Hanson; Axel Schambach; Hans Kreipe; Susan Moir; Joshua D. Milner; Petra Schwille; Stefan Mundlos; Christoph Klein

A primary immunodeficiency syndrome caused by loss-of-function mutations in the IL-21 receptor exhibits impaired B, T, and NK cell function.

Collaboration


Dive into the Axel Schambach's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ute Modlich

Hannover Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tobias Cantz

Hannover Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge